furan has been researched along with rosiglitazone in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chen, WM; Hou, W; Huang, MY; Lin, J; Sun, PH; Wang, F | 1 |
2 other study(ies) available for furan and rosiglitazone
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
5-Benzylidene-3,4-dihalo-furan-2-one derivatives inhibit human leukemia cancer cells through suppression of NF-κB and GSK-3β.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Furans; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; HeLa Cells; HT29 Cells; Humans; Leukemia; Membrane Potential, Mitochondrial; NF-kappa B; PPAR gamma; Proto-Oncogene Proteins c-bcl-2; Rosiglitazone; Thiazolidinediones; U937 Cells; Up-Regulation | 2015 |